Peripheral T-Cell Lymphomas-Not Otherwise Specified: A Shrinking Entity?
Peripheral T-cell lymphomas-not otherwise specified (PTCL-NOS) is now considered a heterogeneous group of distinct molecular subtypes with varied natural history and clinical outcome. Although the standard treatment approach remains the same for all subtypes of PTCL-NOS, these findings will have significant impact on the management of patients with PTCL-NOS as important evidence from clinical trials get translated into routine clinical practice.
Category
  • T-Cell Lymphomas
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma: Is it Time to Consider CAR T for All?
There is a clear need for clinicians to receive education regarding the special considerations for the administration of CAR T-cell therapy in appropriately selected patients, the unique spectrum of treatment-related adverse events and the effective management strategies. More importantly, clinicians should refer appropriate patients for participation in well-designed clinical studies to facilitate the development of CAR T-cell therapies. 
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Smoldering Multiple Myeloma: What is the Threshold to Start Treatment?
To optimize patient outcomes, clinicians need to understand the risks and benefits of early intervention for smoldering multiple myeloma based on risk stratification and the importance of enrolling patients in clinical trials examining early intervention.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Updates in the Management of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Sequencing Therapy and the Role of MRD Testing
There is a continuing need to educate hematologists and oncologists about the challenges and special considerations involved in the management of patients with CLL/SLL so that they can make informed clinical decisions and develop an individualized treatment plan for their patients.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the New NCCN Guidelines for Pediatric Cancers: Advancements in the Management of Pediatric Acute Lymphoblastic Leukemia
The NCCN Guidelines for pediatric ALL will help inform clinicians about treatment approaches and will shed light on new prognostic markers that could be targeted in pediatric ALL to enhance therapeutic efficacy and minimize treatment-related toxicities.
Category
  • Acute Lymphoblastic Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Ovarian Cancer
More than ever before, gynecologic surgeons, oncologists, and pathologists need to work together to assess treatment options for each patient.
Category
  • Ovarian Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: New Agents for Soft Tissue Sarcoma and Gastrointestinal Stromal Tumors
Pharmacists play a critical role in patient education, monitoring, and management of treatment-related toxicities and would benefit from a comprehensive review of novel treatments for soft tissue sarcomas and gastrointestinal stromal tumors.
Category
  • Soft Tissue Sarcomas
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the New NCCN Guidelines for Pediatric Cancers: Multidisciplinary Management of Wilms Tumor (Nephroblastoma)
The NCCN Guidelines for Wilms tumor (nephroblastoma) are new guidelines that will address management of favorable histology Wilms tumor in children. Treatment needs to be carefully selected to maximize cure and minimize long-term toxicities, such as renal failure, cardiac toxicity, and hypertension, because these children with favorable histology Wilms tumor generally have long-term survival if they receive appropriate management.
Category
  • Wilms Tumor (Nephroblastoma)
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
New Approaches to Multiple Myeloma Therapy
The goal of this activity is to increase participants’ competence and performance in applying the best evidence-based, guideline-driven treatment options to optimize the care of patients with multiple myeloma and improve patient outcomes. 
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Lung Cancer
This tumor board will discuss how to select the most appropriate therapy for patients with lung cancer using a case-based format.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation

Pages